Trials / Completed
CompletedNCT06315335
A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants
A SINGLE CENTER, RANDOMIZED, INVESTIGATOR- AND PARTICIPANT-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, ETHNOBRIDGING PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE-DOSE OF UCB9741 IN HEALTHY CAUCASIAN AND JAPANESE PARTICIPANTS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is investigate the safety, tolerability and pharmacokinetic of UCB9741 after 2 dose strengths administered subcutaneous as a single-dose in healthy Caucasian and Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UCB9741 | Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period. |
| DRUG | Placebo | Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period. |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2025-01-01
- Completion
- 2025-01-01
- First posted
- 2024-03-18
- Last updated
- 2025-11-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06315335. Inclusion in this directory is not an endorsement.